Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

Matthew R. Deshotels, Salim S. Virani, Christie M. Ballantyne

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


Purpose of Review: The 2015 American College of Cardiology (ACC)/American Heart Association (AHA) Focused Update of Secondary Prevention Lipid Performance Measures removed low-density lipoprotein cholesterol (LDL-C) assessment as a performance measure. This review discusses the evidence supporting the importance of lipid monitoring in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Recent Findings: The 2018 AHA/ACC Multisociety cholesterol guideline (as did the 2013 guideline) recommends a lipid panel after initiating lipid-lowering therapy to monitor adherence and medication efficacy. The 2018 guideline also recommends adding nonstatin therapy in very-high-risk ASCVD patients with LDL-C ≥70 mg/dL despite maximally tolerated statin therapy. Summary: The removal of LDL-C monitoring as a performance measure is not consistent with the 2018 cholesterol guidelines. Given the importance of monitoring lipid-lowering medication efficacy and adherence and optimally reducing LDL-C in very-high-risk patients with additional evidence-based nonstatin therapy, LDL-C assessment after initiating lipid-lowering therapy should be reinstated as a performance measure for patients with ASCVD.

Original languageEnglish
Article number116
JournalCurrent Cardiology Reports
Issue number9
Publication statusPublished - Sept 2021
Externally publishedYes


  • Atherosclerosis
  • Low-density lipoprotein-C (LDL-C)
  • Performance measure
  • Statin


Dive into the research topics of 'Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?'. Together they form a unique fingerprint.

Cite this